Porownywarka

Oxytocin vs MOTS-c side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

OxytocinMOTS-c

Udostępnij porównanie peptydów

Wlasciwosc	Oxytocin	MOTS-c
Kategoria	Hormonalne	Hormonalne
Znany tez jako	Pitocin, Syntocinon, The Love Hormone	Mitochondrial ORF of the 12S rRNA type-c
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA approved for labor and postpartum use; other uses remain under research Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical; source notes early human studies beginning and FDA Category 2 status pending formal reclassification review. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Social bonding, anxiety, trust, emotional wellbeing	Metabolic health, exercise performance, insulin sensitivity
Jak dziala	Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways.	MOTS-c is presented as a mitochondrial peptide with a proposed metabolic signaling role. The source links its activity to AMPK activation after effects on folate-AICAR-one-carbon metabolism, with downstream research interest in fatty-acid oxidation, glucose handling, and mitochondrial biogenesis. It also reports that MOTS-c may enter the nucleus during metabolic stress and influence stress-response genes, a mechanism that remains under investigation.
Typowe dawkowanie	10-24 IU intranasal as needed · As needed · Intranasal	5-10 mg weekly · 1-3x weekly
Dawkowanie z badań	10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research)	5-10 mg daily · Variable by protocol · Subcutaneous injection
Typowy czas trwania	Single dose or short-term use	Variable by protocol
Podanie	IV in obstetric labeling; intranasal in research contexts	Subcutaneous injection
Timing	As needed in studied social or bonding contexts With or without food	Morning or pre-workout Empty stomach
Poziom dowodów	Zatwierdzone przez FDA	Przedkliniczne
Mozliwe skutki uboczne	Headache Nausea and vomiting Uterine hypertonicity (Relevant to obstetric use and uterine activity.) +4 więcej Blood pressure changes Arrhythmias Water intoxication (Reported with prolonged use in the source.) Maternal and fetal complications (The source flags this risk in obstetric contexts.)	Generally well-tolerated (Reported by the source as a general tolerability note; not a complete safety assessment.) Injection-site reactions, including persistent bumps (Reported local reaction.) Palpitations (Reported systemic effect.) +5 więcej Nausea and bloating (Reported gastrointestinal effects.) Fatigue (Reported effect.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Potential interactions with metformin (Interaction concern reported by the source; clinical significance is not established here.) Unknown long-term effects (The source notes lack of long-term safety certainty.)
Podsumowanie researchu	The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses.	The supplied source reports strong preclinical interest in MOTS-c, especially in mouse models where it is associated with improved insulin sensitivity, resistance to diet-induced obesity, and longer treadmill running in older animals. Human evidence in the source is more limited and described as observational: exercise was reported to increase MOTS-c in skeletal muscle and circulation. The source also states that, as of 2026, completed published randomized human trials have not shown supplemental MOTS-c to produce weight loss, metabolic improvement, or longevity effects in people. It is also noted as relevant to anti-doping monitoring, reinforcing its experimental and performance-related research context.
Referencje	Peptibase peptides Peptibase peptides +3 więcej Peptibase peptides Peptibase peptides Peptibase peptides	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Oxytocin

MOTS-c

Kategoria

Hormonalne

Znany tez jako

Pitocin, Syntocinon, The Love Hormone

Mitochondrial ORF of the 12S rRNA type-c

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA approved for labor and postpartum use; other uses remain under research

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical; source notes early human studies beginning and FDA Category 2 status pending formal reclassification review.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Social bonding, anxiety, trust, emotional wellbeing

Metabolic health, exercise performance, insulin sensitivity

Jak dziala

Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways.

MOTS-c is presented as a mitochondrial peptide with a proposed metabolic signaling role. The source links its activity to AMPK activation after effects on folate-AICAR-one-carbon metabolism, with downstream research interest in fatty-acid oxidation, glucose handling, and mitochondrial biogenesis. It also reports that MOTS-c may enter the nucleus during metabolic stress and influence stress-response genes, a mechanism that remains under investigation.

Typowe dawkowanie

10-24 IU intranasal as needed · As needed · Intranasal

5-10 mg weekly · 1-3x weekly

Dawkowanie z badań

10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research)

5-10 mg daily · Variable by protocol · Subcutaneous injection

Typowy czas trwania

Single dose or short-term use

Variable by protocol

Podanie

IV in obstetric labeling; intranasal in research contexts

Subcutaneous injection

Timing

As needed in studied social or bonding contexts

With or without food

Morning or pre-workout

Empty stomach

Poziom dowodów

Zatwierdzone przez FDA

Przedkliniczne

Mozliwe skutki uboczne

Headache
Nausea and vomiting
Uterine hypertonicity (Relevant to obstetric use and uterine activity.)

+4 więcej

Blood pressure changes
Arrhythmias
Water intoxication (Reported with prolonged use in the source.)
Maternal and fetal complications (The source flags this risk in obstetric contexts.)

Generally well-tolerated (Reported by the source as a general tolerability note; not a complete safety assessment.)
Injection-site reactions, including persistent bumps (Reported local reaction.)
Palpitations (Reported systemic effect.)

+5 więcej

Nausea and bloating (Reported gastrointestinal effects.)
Fatigue (Reported effect.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Potential interactions with metformin (Interaction concern reported by the source; clinical significance is not established here.)
Unknown long-term effects (The source notes lack of long-term safety certainty.)

Podsumowanie researchu

The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses.

The supplied source reports strong preclinical interest in MOTS-c, especially in mouse models where it is associated with improved insulin sensitivity, resistance to diet-induced obesity, and longer treadmill running in older animals. Human evidence in the source is more limited and described as observational: exercise was reported to increase MOTS-c in skeletal muscle and circulation. The source also states that, as of 2026, completed published randomized human trials have not shown supplemental MOTS-c to produce weight loss, metabolic improvement, or longevity effects in people. It is also noted as relevant to anti-doping monitoring, reinforcing its experimental and performance-related research context.

Referencje

Peptibase peptides Peptibase peptides

+3 więcej

Peptibase peptides Peptibase peptides Peptibase peptides

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły